Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550235 | 0.79 | KDM4E (0.43) | S1PR1S1PR3S1PR5DRD2S1PR4 | |
| SCHEMBL14968300 | 0.79 | ALDH1A1 (0.41) | S1PR1S1PR3S1PR5DRD2OPRM1 | |
| SCHEMBL22769422 | 0.77 | DRD2 (0.34) | S1PR1S1PR3S1PR5DRD2HRH2 | |
| SCHEMBL3293583 | 0.77 | DRD2 (0.34) | S1PR1S1PR3S1PR5DRD2OPRM1 | |
| SCHEMBL23634869 | 0.77 | HRH2 (0.34) | S1PR1S1PR3S1PR5DRD2HRH2 | |
| SCHEMBL12685679 | 0.76 | DRD2 (0.36) | DRD2OPRM1OPRK1 | |
| SCHEMBL14968314 | 0.75 | HRH2 (0.45) | S1PR1S1PR3S1PR5S1PR4HRH2 | |
| SCHEMBL19604907 | 0.75 | S1PR1 (0.42) | S1PR1S1PR3S1PR5DRD2S1PR4 | |
| SCHEMBL4546599 | 0.74 | OPRL1 (0.37) | DRD2OPRM1 | |
| SCHEMBL21246950 | 0.74 | S1PR1 (0.38) | S1PR1S1PR3S1PR5DRD2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | S1PR1 4568/4885S1PR3 4483/4885S1PR5 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.